 Home > Biochemical Engineering > Inhibitors > N1-(3,5-Dimethoxyphenyl)-N2-(1-methylethyl)-N1-[3-(1-methyl-1H-pyrazol-4-yl)-6-quinoxalinyl]-1,2-ethanediamine for Sale > Erdafitinib CAS NO 1346242-81-6 99% high purity DIDEU white crystalline powder

Erdafitinib CAS NO 1346242-81-6 99% high purity DIDEU white crystalline powder buy - large image1

Erdafitinib CAS NO 1346242-81-6 99% high purity DIDEU white crystalline powder buy - image1

Erdafitinib CAS NO 1346242-81-6 99% high purity DIDEU white crystalline powder buy - image2

Erdafitinib CAS NO 1346242-81-6 99% high purity DIDEU white crystalline powder buy - image3

Erdafitinib CAS NO 1346242-81-6 99% high purity DIDEU white crystalline powder buy - image4

Erdafitinib CAS NO 1346242-81-6 99% high purity DIDEU white crystalline powder

Name: Erdafitinib CAS NO 1346242-81-6 99% high purity DIDEU white crystalline powder
Brand: Dideu
SKU: pr2607032754
Price: 1 USD
Availability: InStock

TDS 268 Inquiries

Unit Price: Get Latest Price 

CAS No.:

1346242-81-6

Grade:

Industrial Grade

Content:

99%

Port:

shanghai

Brand:

Dideu

Packaging:

25kg/Drum

Price valid (until):

2026-08-03

Contact Supplier

 Chat Now

Shaanxi Dideu Medichem Co. Ltd

Company Type:

Manufactory

Location:

China

Qualification:

Main Products:

Chemical Pesticides,Food Additives,Agrochemicals,Active Pharm Ingredients,Flavors and Fragrances,Chemical Catalyst

 Visit Store

Product Description
Seller Information
Inquiry History

Description

Shop Erdafitinib CAS NO 1346242-81-6 99% high purity DIDEU white crystalline powder-Detailed Image 1

English synonyms

Erdafitinib;Erdafitinib(JNJ-42756493);N-(3,5-dimethoxyphenyl)-N'-(1-methylethyl)-N-[3-(1-methyl-1H-pyrazol-4-yl)quinoxalin-6-yl]ethane-1,2-diamine;N1-(3,5-Dimethoxyphenyl)-N2-(1-methylethyl)-N1-[3-(1-methyl-1H-pyrazol-4-yl)-6-quinoxalinyl]-1,2-ethanediamine;SuftaChemicalbooklanZine;N-(3,5-Dimethoxyphenyl)-N'-isopropyl-N-[3-(1-methyl-1H-pyrazol-4-yl)-6-quinoxalinyl]-1,2-ethanediamine;N1-(3,5-dimethoxyphenyl)-N2-isopropyl-N1-(3-(1-methyl-1H-pyrazol-4-yl)quinoxalin-6-yl)ethane-1,2-diamine;ERDAFITINIB;JNJ-42756493;JNJ42756493;JNJ42756493

Edatinib is a kinase inhibitor targeting FGFR, used to treat adult patients with locally advanced or metastatic urothelial carcinoma who develop disease progression during or after platinum based chemotherapy. Patients with FGFR3 or FGFR2 gene mutations, including those who have received neoadjuvant or adjuvant platinum based chemotherapy for 12 months.

Erdafitinib (JNJ-42756493) is an effective, selective, and orally active inhibitor of fibroblast growth factor receptor FGFR, with potential anti-tumor activity. Erdafitinib can also bind to RET (c-RET), CSF-1R, PDGFR - α/PDGFR - β, FLT4, Kit (c-Kit), and VEGFR-2 and induce cell apoptosis. In vitro studies have shown that JNJ-42756493 is an effective and orally active pan FGFR tyrosine kinase inhibitor, with low concentration molar range for all members of the FGFR family (FGFR1-4) and minimal effect on VEGFR activity. In vitro, cells treated with JNJ-42756493 showed reduced proliferation, increased apoptotic death, and decreased cell survival. In vivo studies showed that treatment with JNJ-42756493 delayed tumor growth in NCI-H716, while tumor volume increased when drug treatment was withdrawn. JNJ-42756493 has good drug like properties and is widely distributed in lung, liver, and kidney tissues. At effective doses, JNJ-42756493 is well tolerated, exhibits dose-dependent anti-tumor activity, and has a pharmacological regulatory effect on FGFR and its downstream pathway components in tumors.

Advantage
1)Widely used for rinsing stains
2)Active at 20 ° C
3)Has antibacterial properties
4)Strong deodorization effect
5)Small amount of addition
6)Not causing allergies
7)Easy to use
8)For human safety
9)Safe for fibers and colors
10)No VOC release
11)Chlorine free
12)No Seveso

matters needing attention

Safe storage: 4-Butylresorcinol should be stored in a dry, well ventilated environment, away from heat sources, fire sources, and open flames.

Personal protection: Appropriate personal protective equipment such as gloves, goggles, and protective clothing should be worn during operation.

Environmental impact: When handling 4-n-butylresorcinol, it should be avoided from entering the environment to prevent adverse effects on the environment and health.

Item	Standard	Test Results
Identification	A.H-NMR:Comply with the structure	Complies
	B.LC-MS:Comply with the structure	Complies
	C.The IR spectrum of sample should be identical with that of reference standard.	Complies
	D.HPLC-ESI-MS	Complies
	The retention time of the major peak in the chromatogram of the Assay preparation corresponds to that in the chromatogram of the Standard preparation, as obtained in the Assay.	Complies
Loss on drying	≤2.0%	0.19%
Heavy metals	≤10 ppm	<10ppm
Water	≤1.0%	0.10%
Sulphated ash	≤0.5% determined on 1.0 g.	0.01%
Residue on ignition	≤0.1%	0.03%
Related Substances	Unspecified impurities: for each impurity ≤0.10%	<0.10%
Related Substances	Total Impurity ≤0.5%	0.18%
Purity	≥99.0%	99.70%
Assay	99.0%~101.0% (anhydrous substance).	99.80%
Storage	Preserve in well-closed, light-resistant and airtight containers.	Complies

Shop Erdafitinib CAS NO 1346242-81-6 99% high purity DIDEU white crystalline powder-Detailed Image 2

Our Services

a) Free sample can be supplied.
b) Guide our clients by professional knowledge and teach them how to use our product after sales.
c) Accept SGS, BV any other third-party inspection before loading.
d) High quality best price Guaranteed.

Shop Erdafitinib CAS NO 1346242-81-6 99% high purity DIDEU white crystalline powder-Detailed Image 3

Shop Erdafitinib CAS NO 1346242-81-6 99% high purity DIDEU white crystalline powder-Detailed Image 4

Why do you choose Dideu Industries as your partner?
A) High quality can be guaranteed. Dideu Industries since 1975 are reputed chemical manufacturer and are Certified by ISO 9001;2015 and have GMP certification.Free sample can be arranged before shipment and SGS,BV and other third party inspection company are accepted before loading.For regular customers, we accept L/C 180 Days, D/P,D/A payment term. If there is any quality problem after goods arrive. Dideu Industries will do fully payment refund.
B) Best price can be guaranteed. As Dideu Industries are integrated pharmaceuticals and chemicals producer, the production cost can be controlled and price will be definitely more competitive than China trading companies.
C) Professional enginners from Dideu Industries will give professional usage guide and services after sales.
D) Dideu Industries work 7×24 hours and your request will be processed by our professional staff in different shift period.

Shop Erdafitinib CAS NO 1346242-81-6 99% high purity DIDEU white crystalline powder-Detailed Image 5

Packaging and Shipping

Our normal packaging is 25kgs/Drum and 200kgs/Drum.
The packaging can be customized. the shipping term can be by sea, by air, and sample or small quantity can be shipped by DHL, FEDEX, EMS and TNT.

Shop Erdafitinib CAS NO 1346242-81-6 99% high purity DIDEU white crystalline powder-Detailed Image 6

Shop Erdafitinib CAS NO 1346242-81-6 99% high purity DIDEU white crystalline powder-Detailed Image 11

Our company has various payment methods.

For example: bank transfer, LC at sight,and so on.

Shop Erdafitinib CAS NO 1346242-81-6 99% high purity DIDEU white crystalline powder-Detailed Image 12

ECHEMI Editorial Reference

Erdafitinib (JNJ-42756493) is a potent and orally available FGFR family inhibitor; inhibits FGFR1/2/3/4 with IC50s of 1.2, 2.5, 3.0 and 5.7 nM, respectively.
In early April of 2019, the US FDA approved Janssen Pharmaceutical Companies' brand name Balversa (erdafitinib) as the first-ever fibroblast growth factor receptor (FGFR) kinase inhibitor indicated for patients with locally advanced or metastatic urothelial carcinoma, with susceptible FGFR3 or FGFR2 genetic alterations, that has progressed during or following platinum-containing chemotherapy, including within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy. At the same time, the FDA also approved the therascreen FGFR RGQ RT-PCR Kit (Qiagen) for utilization as a companion diagnostic with erdafitinib for selecting patients for the indicated therapy. Erdafitinib's innovation lies in the fact that it is the first personalized treatment targeting susceptible FGFR genetic alterations for patients with metastatic bladder cancer, which demonstrates the design of erdafitinib in developing more personalized and precision medicines with the capacity to target cancer treatment to a patient's specific genetic mutation. Considering urothelial cancer is statistically the fourth most common kind of cancer in the world, the introduction of erdafitinib offers a welcome new option in the ever-expanding therapeutic tool kit to treat such prevalent medical conditions. Nevertheless, although erdafitinib was granted Breakthrough Therapy designation and Accelerated Approval from the FDA so as to allow the agency to focus on and expedite the approval process for a medication indicated for a serious condition that fills an unmet medical need using clinical trial data that is believed to predict a genuine clinical benefit for patients with the given condition, such designations mean further ongoing clinical trials are necessary to confirm the clinical benefit of erdafitinib going forward.|Erdafitinib is an oral small molecule inhibitor of fibroblast growth factor receptors (FGFR) 1 to 4 that is used in the therapy of locally advanced, unresectable or metastatic urothelial carcinoma. Erdafitinib has been associated with a high rate of serum enzyme elevations during therapy, but has not been linked to cases of clinically apparent acute liver injury.|Erdafitinib is an orally bioavailable, pan fibroblast growth factor receptor (FGFR) inhibitor with potential antineoplastic activity. Upon oral administration, erdafitinib binds to and inhibits FGFR, which may result in the inhibition of FGFR-related signal transduction pathways and thus the inhibition of tumor cell proliferation and tumor cell death in FGFR-overexpressing tumor cells. FGFR, upregulated in many tumor cell types, is a receptor tyrosine kinase essential to tumor cell proliferation, differentiation and survival.

Certificates

Basic Info

Product Name:

N1-(3,5-Dimethoxyphenyl)-N2-(1-methylethyl)-N1-[3-(1-methyl-1H-pyrazol-4-yl)-6-quinoxalinyl]-1,2-ethanediamine

Other Name:

1,2-Ethanediamine,N1-(3,5-dimethoxyphenyl)-N2-(1-methylethyl)-N1-[3-(1-methyl-1H-pyrazol-4-yl)-6-quinoxalinyl]-;N1-(3,5-Dimethoxyphenyl)-N2-(1-methylethyl)-N1-[3-(1-methyl-1H-pyrazol-4-yl)-6-quinoxalinyl]-1,2-ethanediamine;Erdafitinib;JNJ 42756493;Balversa;1620332-47-9

CAS No.:

1346242-81-6

Molecular Formula:

C25H30N6O2

InChIKeys:

InChIKey=OLAHOMJCDNXHFI-UHFFFAOYSA-N

Molecular Weight:

446.54

Exact Mass:

446.54

UNII:

890E37NHMV

NCI Thesaurus Code:

C103273

ATC Code:

L - Antineoplastic and immunomodulating agents

Categories:

Inhibitors

Characteristics

PSA:

77.3

XLogP3:

3.2

Density:

1.2±0.1 g/cm3

Flash Point:

354.4±31.5 °C

Refractive Index:

1.618

Water Solubility:

<1 mg/mL

Research

Class:

Pan-FGFR tyrosine kinase inhibitor (FGFR1-4); antineoplastic (ATC L01EN01)

Status:

Approved (FDA accelerated approval 2019-04-12; converted to regular approval 2024-01-19; EMA approval 2024-08)

Mechanism:

Erdafitinib is an orally bioavailable, functionally selective small-molecule inhibitor of fibroblast growth factor receptors 1-4 (FGFR1-4). It inhibits FGFR tyrosine kinase activity (IC50 1.2-5.7 nM), blocking downstream RAS-MAPK/ERK and PI3K-AKT signaling that drives proliferation and survival of tumor cells harboring activating FGFR alterations (mutations, amplifications, or fusions). Rapid lysosomal uptake contributes to prolonged inhibition of FGFR signaling.

EC50 (Fgfr1 Ic50):

1.2 nM

EC50 (Fgfr3 Ic50):

3.0 nM

EC50 (Fgfr2 Ic50):

2.5 nM

EC50 (Fgfr4 Ic50):

5.7 nM

EC50 (Vegfr2 Ic50):

36.8 nM (approximately 30-fold selectivity vs FGFR1)

Source:

Perera TPS, et al. Mol Cancer Ther. 2017;16(6):1010-1020.DOI

Clinical Development:

NCT02365597; NCT03390504

FDA:

Balversa (approved 2019-04-12)

References

ChEMBL:

DrugBank:

KEGG DRUG:

PubChem:

Literature:

FDA: Approval announcement 2024-01-19; FDA: BALVERSA label (NDA 212018, BLC2001); NEJM: Loriot et al. (2023) — THOR Cohort 1; NEJM: Loriot et al. (2019) — BLC2001; Mol Cancer Ther: Perera et al. (2017) — discovery pharmacology

Disclaimer:

Erdafitinib (Balversa) is a prescription medicine approved by the US FDA and the EMA for specific oncology indications. ECHEMI lists this product for industrial sourcing and supply-chain reference only. Product information on ECHEMI is provided for sourcing and specification reference. It is not medical advice, a clinical recommendation, or a substitute for approved therapy. Always verify regulatory status, purity, and intended use with the supplier and applicable authorities before purchase or use.

See More N1-(3,5-Dimethoxyphenyl)-N2-(1-methylethyl)-N1-[3-(1-methyl-1H-pyrazol-4-yl)-6-quinoxalinyl]-1,2-ethanediamine Properties 

Hazard Identification

Classification of the substance or mixture

Acute toxicity - Category 4, Oral

Skin sensitization, Sub-category 1B

Serious eye damage, Category 1

Reproductive toxicity, Category 2

Specific target organ toxicity â repeated exposure, Category 1

GHS label elements, including precautionary statements

Precautionary statement(s)
Pictogram(s)
Signal word	Danger
Hazard statement(s)	H302 Harmful if swallowed H317 May cause an allergic skin reaction H318 Causes serious eye damage H361 Suspected of damaging fertility or the unborn child H372 Causes damage to organs through prolonged or repeated exposure
Prevention	P264 Wash ... thoroughly after handling. P270 Do not eat, drink or smoke when using this product. P261 Avoid breathing dust/fume/gas/mist/vapours/spray. P272 Contaminated work clothing should not be allowed out of the workplace. P280 Wear protective gloves/protective clothing/eye protection/face protection/hearing protection/... P203 Obtain, read and follow all safety instructions before use. P260 Do not breathe dust/fume/gas/mist/vapours/spray.
Response	P301+P317 IF SWALLOWED: Get medical help. P330 Rinse mouth. P302+P352 IF ON SKIN: Wash with plenty of water/... P333+P317 If skin irritation or rash occurs: Get medical help. P321 Specific treatment (see ... on this label). P362+P364 Take off contaminated clothing and wash it before reuse. P305+P354+P338 IF IN EYES: Immediately rinse with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing. P317 Get medical help. P318 IF exposed or concerned, get medical advice. P319 Get medical help if you feel unwell.
Storage	P405 Store locked up.
Disposal	P501 Dispose of contents/container to an appropriate treatment and disposal facility in accordance with applicable laws and regulations, and product characteristics at time of disposal.

Other hazards which do not result in classification

no data available

Handling and Storage

Precautions for safe handling

Handling in a well ventilated place. Wear suitable protective clothing. Avoid contact with skin and eyes. Avoid formation of dust and aerosols. Use non-sparking tools. Prevent fire caused by electrostatic discharge steam.

Conditions for safe storage, including any incompatibilities

Store the container tightly closed in a dry, cool and well-ventilated place. Store apart from foodstuff containers or incompatible materials.

See More N1-(3,5-Dimethoxyphenyl)-N2-(1-methylethyl)-N1-[3-(1-methyl-1H-pyrazol-4-yl)-6-quinoxalinyl]-1,2-ethanediamine Safety Data Sheet 

Seller Information

Business Type:
Manufactory

Main Products:
Chemical Pesticides,Food Additives,Agrochemicals,Active Pharm Ingredients,Flavors and Fragrances,Chemical Catalyst

Location:
https://www.dideu.com/en/

Payment Terms:
TT against copy of documents,D/P,L/C,D/A,O/A,TT against B/L draft before shipment,100% TT in advance

Average lead Time:
7

Total Annual Revenue:
Above $100 million

Total Employees:
Above 1000

Year of Establishment:
2016

Certifications:
ISO Certificate,REACH

Company Profile
">Company Profile

Inquiry History

268 Inquiries

Country	Product	Purchase Quantity	Date Posted
Germany	High Quality Erdafitinib 99% powder 1346242-81-6 Erdafitinib	1 G	Aug 25, 2026
Vietnam	High Quality Erdafitinib 99% powder 1346242-81-6 Erdafitinib	1 G	Aug 18, 2026
United States	High Quality Erdafitinib 99% powder 1346242-81-6 Erdafitinib	1 G	Jul 26, 2026
Australia	High Quality Erdafitinib 99% powder 1346242-81-6 Erdafitinib	1 G	Aug 14, 2026
Poland	High Quality Erdafitinib 99% powder 1346242-81-6 Erdafitinib	1 G	Jul 28, 2026
Canada	Best Price Pure 98% HPLC JNJ-42756493 Erdafitinib Powder CAS 1346242-81-6	500 MG	Sep 1, 2026
Canada	Best Price Pure 98% HPLC JNJ-42756493 Erdafitinib Powder CAS 1346242-81-6	500 MG	Aug 25, 2026
United States	Factory Supply Erdafitinib CAS 1346242-81-6 99% High Purity FGFR Inhibitor API Powder	1 G	Sep 3, 2026
United States	Hot Selling ERDAFITINIB 1346242-81-6 Factory Supply Raw Materials High Qulity Wholesale price	3 MT	Jul 5, 2026
Australia	Erdafitinib	1 G	Jul 18, 2026
Germany	Erdafitinib	500 MG	Jul 28, 2026
Cyprus	Erdafitinib	1 G	Jul 22, 2026
Bulgaria	Erdafitinib	500 MG	Jun 18, 2026
Switzerland	1g Erdafitinib raw powder >99% purity	1 G	May 22, 2026
Georgia	Erdafitinib	1 G	Aug 19, 2026
United States	Erdafitinib	1 G	Aug 27, 2026
United States	Erdafitinib	1 G	Aug 29, 2026
Germany	Erdafitinib	1 G	Aug 31, 2026
United States	Erdafitinib	1 G	Aug 31, 2026
Saudi Arabia	Erdafitinib	1 G	Aug 31, 2026

Go to Page

Post an enquiry for this product

More Choices Find All Products for Sale 

Product Name	Grade / Content	Price	Supplier Name	Details
ERDAFITINIB high quality	/	$1-1.3/BOU FOB	Nanjing Paron Technology Co., Ltd	Inquiry
N1-(3,5-Dimethoxyphenyl)-N2-isopropyl-N1-(3-(1-methyl-1H-pyrazol-4-yl)quinoxalin-6-yl)ethane-1,2-diamine 99%	/		Conier Chem&Pharma Limited	Inquiry
Erdafitinib 1346242-81-6	/		Shandong zhishang chemical Co.,Ltd	Inquiry
Erdafitinib CAS 1346242-81-6 JNJ-42756493 Balversa FGFR Tyrosine Kinase Inhibitor Anti-Cancer API 99% Purity	Pharmaceutical Grade/99	$5-6/MT FOB	Hangzhou Hyper Chemicals Limited	Inquiry
ERDAFITINIB 98% yellow powder 1346242-81-6 Senwayer	Pharmaceutical Grade/98		Dingwang Technology (Wuhan) Co., Ltd.	Inquiry